214 related articles for article (PubMed ID: 33790110)
1. Construction of a Risk Prediction Model of Extended Release Oxycodone Tablet-Induced Nausea and Clarification of Predictive Factors.
Kumai M; Imai S; Kato S; Koyanagi R; Tsuruga K; Yamada T; Takekuma Y; Sugawara M
Biol Pharm Bull; 2021; 44(4):593-598. PubMed ID: 33790110
[TBL] [Abstract][Full Text] [Related]
2. Predictive factors for nausea or vomiting in patients with cancer who receive oral oxycodone for the first time: is prophylactic medication for prevention of opioid-induced nausea or vomiting necessary?
Kanbayashi Y; Hosokawa T
J Palliat Med; 2014 Jun; 17(6):683-7. PubMed ID: 24702605
[TBL] [Abstract][Full Text] [Related]
3. Incidence of nausea and vomiting induced by oxycodone administered with prochlorperazine in Japanese cancer patients.
Yamada T; Kanazawa Y; Aoki Y; Uchida E
J Nippon Med Sch; 2015; 82(2):100-5. PubMed ID: 25959201
[TBL] [Abstract][Full Text] [Related]
4. Efficacy of Prophylactic Treatment for Oxycodone-Induced Nausea and Vomiting Among Patients with Cancer Pain (POINT): A Randomized, Placebo-Controlled, Double-Blind Trial.
Tsukuura H; Miyazaki M; Morita T; Sugishita M; Kato H; Murasaki Y; Gyawali B; Kubo Y; Ando M; Kondo M; Yamada K; Hasegawa Y; Ando Y
Oncologist; 2018 Mar; 23(3):367-374. PubMed ID: 29038236
[TBL] [Abstract][Full Text] [Related]
5. Efficacy and tolerability of once-daily OROS hydromorphone and twice-daily extended-release oxycodone in patients with chronic, moderate to severe osteoarthritis pain: results of a 6-week, randomized, open-label, noninferiority analysis.
Hale M; Tudor IC; Khanna S; Thipphawong J
Clin Ther; 2007 May; 29(5):874-888. PubMed ID: 17697906
[TBL] [Abstract][Full Text] [Related]
6. The Risk of Ischemic Cardio- and Cerebrovascular Events Associated with Oxycodone-Naloxone and Other Extended-Release High-Potency Opioids: A Nested Case-Control Study.
Jobski K; Kollhorst B; Garbe E; Schink T
Drug Saf; 2017 Jun; 40(6):505-515. PubMed ID: 28194654
[TBL] [Abstract][Full Text] [Related]
7. Controlled Release of Oxycodone as an Opioid Titration for Cancer Pain Relief: A Retrospective Study.
Zhao S; Xu C; Lin R
Med Sci Monit; 2020 Mar; 26():e920598. PubMed ID: 32225127
[TBL] [Abstract][Full Text] [Related]
8. Composite measure to assess efficacy/gastrointestinal tolerability of tapentadol ER versus oxycodone CR for chronic pain: pooled analysis of randomized studies.
Merchant S; Provenzano D; Mody S; Ho KF; Etropolski M
J Opioid Manag; 2013; 9(1):51-61. PubMed ID: 23709304
[TBL] [Abstract][Full Text] [Related]
9. Prolonged-Release (PR) Oxycodone/Naloxone Improves Bowel Function Compared with Oxycodone PR and Provides Effective Analgesia in Chinese Patients with Non-malignant Pain: A Randomized, Double-Blind Trial.
Leng X; Zhang F; Yao S; Weng X; Lu K; Chen G; Huang M; Huang Y; Zeng X; Hopp M; Lu G
Adv Ther; 2020 Mar; 37(3):1188-1202. PubMed ID: 32020565
[TBL] [Abstract][Full Text] [Related]
10. Single- and multiple-dose pharmacokinetic evaluation of oxycodone and naloxone in an opioid agonist/antagonist prolonged-release combination in healthy adult volunteers.
Smith K; Hopp M; Mundin G; Leyendecker P; Bailey P; Grothe B; Uhl R; Reimer K
Clin Ther; 2008 Nov; 30(11):2051-68. PubMed ID: 19108793
[TBL] [Abstract][Full Text] [Related]
11. Safety and Tolerability of Biphasic Immediate-Release/Extended-Release Oxycodone/Acetaminophen Tablets: Analysis of 11 Clinical Trials.
Barrett T; Kostenbader K; Nalamachu S; Giuliani M; Young JL
Pain Pract; 2016 Sep; 16(7):856-68. PubMed ID: 26296448
[TBL] [Abstract][Full Text] [Related]
12. Differential effects of food on the bioavailability of controlled-release oxycodone tablets and immediate-release oxycodone solution.
Benziger DP; Kaiko RF; Miotto JB; Fitzmartin RD; Reder RF; Chasin M
J Pharm Sci; 1996 Apr; 85(4):407-10. PubMed ID: 8901078
[TBL] [Abstract][Full Text] [Related]
13. Safety and efficacy of oxycodone/naloxone vs. oxycodone vs. morphine for the treatment of chronic low back pain: results of a 12 week prospective, randomized, open-label blinded endpoint streamlined study with prolonged-release preparations.
Ueberall MA; Mueller-Schwefe GH
Curr Med Res Opin; 2015; 31(7):1413-29. PubMed ID: 25942606
[TBL] [Abstract][Full Text] [Related]
14. Oral oxycodone/naloxone for pain control in cirrhosis: Observational study in patients with symptomatic metastatic hepatocellular carcinoma.
Tovoli F; De Lorenzo S; Samolsky Dekel BG; Piscaglia F; Benevento F; Brandi G; Bolondi L
Liver Int; 2018 Feb; 38(2):278-284. PubMed ID: 28792650
[TBL] [Abstract][Full Text] [Related]
15. Abuse potential, pharmacokinetics, pharmacodynamics, and safety of intranasally administered crushed oxycodone HCl abuse-deterrent controlled-release tablets in recreational opioid users.
Harris SC; Perrino PJ; Smith I; Shram MJ; Colucci SV; Bartlett C; Sellers EM
J Clin Pharmacol; 2014 Apr; 54(4):468-77. PubMed ID: 24243216
[TBL] [Abstract][Full Text] [Related]
16. A comparison of oral controlled-release morphine and oxycodone with transdermal formulations of buprenorphine and fentanyl in the treatment of severe pain in cancer patients.
Nosek K; Leppert W; Nosek H; Wordliczek J; Onichimowski D
Drug Des Devel Ther; 2017; 11():2409-2419. PubMed ID: 28860712
[TBL] [Abstract][Full Text] [Related]
17. Efficacy and tolerability of oral oxycodone and oxycodone/naloxone combination in opioid-naïve cancer patients: a propensity analysis.
Lazzari M; Greco MT; Marcassa C; Finocchi S; Caldarulo C; Corli O
Drug Des Devel Ther; 2015; 9():5863-72. PubMed ID: 26586937
[TBL] [Abstract][Full Text] [Related]
18. Dose proportionality and the effects of food on bioavailability of an immediate-release oxycodone hydrochloride tablet designed to discourage tampering and its relative bioavailability compared with a marketed oxycodone tablet under fed conditions: a single-dose, randomized, open-label, 5-way crossover study in healthy volunteers.
Bass A; Stark JG; Pixton GC; Sommerville KW; Zamora CA; Leibowitz M; Rolleri R
Clin Ther; 2012 Jul; 34(7):1601-12. PubMed ID: 22717418
[TBL] [Abstract][Full Text] [Related]
19. Comparison of the Tolerability Profile of Controlled-Release Oral Morphine and Oxycodone for Cancer Pain Treatment. An Open-Label Randomized Controlled Trial.
Zecca E; Brunelli C; Bracchi P; Biancofiore G; De Sangro C; Bortolussi R; Montanari L; Maltoni M; Moro C; Colonna U; Finco G; Roy MT; Ferrari V; Alabiso O; Rosti G; Kaasa S; Caraceni A
J Pain Symptom Manage; 2016 Dec; 52(6):783-794.e6. PubMed ID: 27742577
[TBL] [Abstract][Full Text] [Related]
20. Positive and negative subjective effects of extended-release oxymorphone versus controlled-release oxycodone in recreational opioid users.
Schoedel KA; McMorn S; Chakraborty B; Potts SL; Zerbe K; Sellers EM
J Opioid Manag; 2011; 7(3):179-92. PubMed ID: 21823549
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
